A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia
ConclusionAlthough the number of patients was limited, FCR appears to be effective with manageable toxicity for treatment-na ïve fit Japanese patients with CD20-positive CLL.Clinical trial numberJapicCTI-132285.
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Clinical Trials | Germany Health | Japan Health | Leukemia | Rituxan | Study | Toxicology